← Back to Clinical Trials
Recruiting NCT06909045

NCT06909045 Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06909045
Status Recruiting
Phase
Sponsor Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Condition Deep Brain Stimulation
Study Type INTERVENTIONAL
Enrollment 130 participants
Start Date 2026-01-27
Primary Completion 2027-02-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Adaptive DBSContinue DBS

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 130 participants in total. It began in 2026-01-27 with a primary completion date of 2027-02-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The objective of the CLOSE-PD study is to compare the efficacy of adaptive deep brain stimulation (aDBS) with continue deep brain stimulation (cDBS) in patients with Parkinson's disease. The main question it aims to answer is: \- whether the change in daily mean ON time without troublesome dyskinesia in aDBS is greater than cDBS over a six-month follow-up period? Researchers will compare aDBS to regular continue deep brain stimulation (cDBS). Participants will: * be set up to cDBS during the first programming visit (visit 2); * be randomized 1:1 to aDBS or cDBS two weeks after visit 2; * follow-up will be at three and six months after visit 2; * complete PD Home diary at baseline, two weeks, three months and at six months after visit 2.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of idiopathic PD based on the UK Brain Bank criteria (Hughes et al. 1992); * Age older than 18 years; * Previous implantation of Medtronic PerceptTM PC/RC DBS electrodes bilateral targeting the STN; * Optimal contact point compatible with aDBS in at least one STN; * Reliable beta peak in at least one STN; * Able to provide informed consent and comply with the study protocol; * Understand the Dutch language. Exclusion Criteria: * Legally incompetent adults; * Patients with ongoing participation in other clinical trials involving neurological interventions; * Inability to recognize the difference between the motor ON or OFF state; * Mild cognitive impairment or dementia; * Pregnancy.

Contact & Investigator

Central Contact

M. Beudel, MD, PhD

✉ closepd@amsterdamumc.nl

📞 +31 20 566 9111

Principal Investigator

Martijn Beudel, MD, PhD

PRINCIPAL INVESTIGATOR

Amsterdam UMC

Frequently Asked Questions

Who can join the NCT06909045 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Deep Brain Stimulation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06909045 currently recruiting?

Yes, NCT06909045 is actively recruiting participants. Contact the research team at closepd@amsterdamumc.nl for enrollment information.

Where is the NCT06909045 trial being conducted?

This trial is being conducted at Leuven, Belgium, Amsterdam, Netherlands, Maastricht, Netherlands, The Hague, Netherlands.

Who is sponsoring the NCT06909045 clinical trial?

NCT06909045 is sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). The principal investigator is Martijn Beudel, MD, PhD at Amsterdam UMC. The trial plans to enroll 130 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology